Literature DB >> 8862841

Localizing muscles for botulinum toxin treatment of focal hand dystonia.

C Geenen1, E Consky, P Ashby.   

Abstract

BACKGROUND: There is currently no consensus on the best way to localize muscles in the forearm for botulinum toxin (BTX) injection. We devised a study to compare electromyography (EMG) with local stimulation through a cannula for localizing forearm muscles for botulinum toxin (BTX) injection, and for predicting the risk of unwanted weakness in non-target muscles.
METHODS: In 12 patients with focal hand dystonia a single "target" muscle, determined by clinical examination to contribute most to the dystonic hand posture, was selected for botulinum toxin injection. The patients were randomized into 2 treatment groups, one in which the target muscle was localized by recording the EMG signals during voluntary contractions (8 patients) and the other in which the target muscle was localized by local electrical stimulation (4 patients). The target muscle was then injected with a standardized dose of BTX.
RESULTS: At follow-up 3 weeks after BTX injection the target muscle was weakened in 7/12 patients (4/8 of the EMG group, and 3/4 of the stimulation group). Additional noninjected muscles, adjacent to the target muscle, were weakened in 5 of these 7 patients, presumably from diffusion of the toxin.
CONCLUSIONS: Localization by stimulation is probably at least as good as EMG. Each technique has certain advantages. Weakness of "non-target" muscles was not consistently predicted by either EMG or stimulation suggesting that BTX diffuses farther than the volume conduction of EMG signals or the spread of effective stimulus current.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862841     DOI: 10.1017/s0317167100038506

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 2.  Task-specific dystonias: historical review--a new look at the classics.

Authors:  Pedro J Garcia-Ruiz
Journal:  J Neurol       Date:  2012-10-10       Impact factor: 4.849

3.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

4.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Treatment of focal dystonia.

Authors:  Amit Batla; Maria Stamelou; Kailash P Bhatia
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

6.  Guidelines for the use of botulinum toxin in movement disorders and spasticity.

Authors:  Afshan Jabeen; Rukmini M Kandadai; Meena A Kannikannan; Rupam Borgohain
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

Review 7.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

8.  Diffusion of botulinum toxins.

Authors:  Matthew A Brodsky; David M Swope; David Grimes
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.